Blue Cloud Softech Solutions Ltd
Incorporated in 1991, Blue Cloud Softech Solutions Ltd is in the business of computer software and data processing services
- Market Cap ₹ 2,064 Cr.
- Current Price ₹ 22.4
- High / Low ₹ 38.0 / 16.5
- Stock P/E 49.1
- Book Value ₹ 11.7
- Dividend Yield 0.00 %
- ROCE 13.4 %
- ROE 8.91 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 435% CAGR over last 5 years
- Company's median sales growth is 38.4% of last 10 years
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 14.0% over last 3 years.
- Debtor days have increased from 81.9 to 122 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Information Technology Information Technology IT - Software Software Products
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 29 | 204 | 502 | 637 | 627 | |
| 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 28 | 196 | 450 | 562 | 551 | |
| Operating Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 8 | 52 | 75 | 76 |
| OPM % | 0.0% | 5% | 4.9% | 6% | 6% | 10% | 9% | 14% | 2.6% | 4.2% | 10% | 12% | 12% |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 7 | 11 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 8 | 49 | 67 | 64 |
| Tax % | 50% | 20% | 20% | 17% | 50% | 0% | 0% | 15% | 26% | 29% | 25% | 35% | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 37 | 44 | 42 | |
| EPS in Rs | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.06 | 0.12 | 0.84 | 0.58 | 0.65 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 8% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 92% |
| 5 Years: | 466% |
| 3 Years: | 180% |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 101% |
| 5 Years: | 435% |
| 3 Years: | 305% |
| TTM: | 0% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 31% |
| 3 Years: | -11% |
| 1 Year: | -28% |
| Return on Equity | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 14% |
| 3 Years: | 14% |
| Last Year: | 9% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 12 | 12 | 5 | 5 | 5 | 11 | 12 | 44 | 44 | 75 |
| Reserves | -7 | -7 | -7 | -7 | -0 | -0 | -0 | 0 | 1 | 22 | 59 | 807 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 18 | 18 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 6 | 112 | 154 | |
| Total Liabilities | 3 | 3 | 5 | 5 | 5 | 5 | 5 | 12 | 14 | 76 | 232 | 1,054 |
| 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 5 | 9 | 52 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 48 | 48 | 779 |
| 1 | 1 | 3 | 3 | 3 | 3 | 3 | 12 | 14 | 23 | 175 | 223 | |
| Total Assets | 3 | 3 | 5 | 5 | 5 | 5 | 5 | 12 | 14 | 76 | 232 | 1,054 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1 | 0 | -1 | 0 | 0 | 0 | 0 | -8 | 0 | 2 | -3 | 46 | |
| 1 | -0 | 0 | 0 | 0 | 0 | 0 | 2 | -1 | -49 | -7 | -48 | |
| 0 | 0 | 1 | 0 | 0 | 0 | 0 | 7 | 0 | 47 | 12 | 2 | |
| Net Cash Flow | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Free Cash Flow | 0 | -0 | -1 | 0 | 0 | 0 | 0 | -7 | -0 | -3 | -10 | -4 |
| CFO/OP | 120% | -2,057% | 12% | 17% | 100% | 0% | -28,267% | 91% | 44% | 17% | 94% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 410 | 251 | 203 | 251 | 291 | 2,847 | 2,655 | 1,642 | 17 | 14 | 110 | 122 |
| Inventory Days | 15 | 0 | 0 | 0 | 0 | |||||||
| Days Payable | 7 | |||||||||||
| Cash Conversion Cycle | 417 | 251 | 203 | 251 | 291 | 2,847 | 2,655 | 1,642 | 17 | 14 | 110 | 122 |
| Working Capital Days | 708 | 471 | 697 | 823 | 1,069 | 10,548 | 9,656 | 18,914 | 155 | 29 | 43 | 40 |
| ROCE % | 2% | 1% | 1% | 1% | 0% | 0% | 0% | 7% | 19% | 53% | 13% |
Insights
In beta| Mar 2028 (P) | Mar 2029 (P) | Mar 2030 (P) | Mar 2031 (P) | Mar 2032 (P) | |
|---|---|---|---|---|---|
| Data Center Planned Capacity MW |
|
||||
Extracted by Screener AI
Documents
Announcements
-
Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015: Press Release On Listing Of Equity Shares Of The Company On The National Stock Exchange Of India Limited
- Blue Cloud shares admitted to NSE Main Board from 17 August 2026; 92.3 crore shares listed.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
- Blue Cloud Softech shares admitted to NSE trading from 17 August 2026, alongside BSE listing.
-
Board Meeting Intimation for Intimation Of Board Meeting Pursuant To Regulation 29 Of The SEBI (LODR) Regulations, 2015.
- Board meets 24 Aug 2026 to consider U.S. healthcare acquisition and preferential fund raising.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 14Th August 2026
- Board approved Q1 FY27 results; completed Rs 372.81 crore Global Impx acquisition and authorised NSE Main Board listing.
-
Board Meeting Intimation for Intimation Of Date Of Board Meeting Pursuant To Regulation 29(1)(A) Of The SEBI (LODR) Regulations, 2015.
- Board meeting on August 14, 2026 to approve Q1 FY27 results; trading window remains closed.
Annual reports
Concalls
-
Jun 2026TranscriptPPTREC
-
Mar 2026TranscriptPPT
Company Overview[1]
The Company operates across high-growth verticals including digital health (BluHealth), AI diagnostics (BluBio), advanced sterilization (BioSter), 5G Fixed Wireless Access (FWA), cybersecurity, and enterprise telecom, supported by a structured SPV-led operating model.